| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 7426- | AgNPs, | CS, | Silver Nanoparticles Formulation of Flower Head's Polyphenols of Cynara scolymus L.: A Promising Candidate against Prostate (PC-3) Cancer Cell Line through Apoptosis Activation |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Lung, | A549 |
| 5597- | Bical, | Bicalutamide: clinical pharmacokinetics and metabolism |
| - | Review, | Pca, | NA |
| 5741- | Buty, | Rad, | Microencapsulated Sodium Butyrate in the Prevention of Acute Radiotherapy Proctitis: Single-Center Prospective Study |
| - | in-vivo, | Pca, | NA |
| 5960- | CEL, | Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers |
| - | Trial, | Pca, | NA |
| 5940- | Cela, | Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway |
| - | in-vivo, | Pca, | PC3 |
| 120- | CUR, | A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation |
| - | Human, | Pca, | NA |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 5386- | docx, | AsP, | Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Pca, | PC3 |
| 6322- | DRE, | LGE, | Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer |
| - | vitro+vivo, | Pca, | DU145 |
| 6802- | EA, | Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate |
| - | Human, | Pca, | NA |
| 7507- | FA, | Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6849- | FBZ, | Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients |
| - | Case Report, | BC, | NA | - | Case Report, | Pca, | NA | - | Case Report, | Melanoma, | NA |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| - | Trial, | Pca, | NA |
| 7107- | GEN, | Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients |
| - | Trial, | Pca, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 7105- | GEN, | Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer |
| - | Trial, | Pca, | NA |
| - | Trial, | Pca, | NA |
| 7245- | Gink, | Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | MCF10 |
| 7258- | Gink, | Ginkgetin inhibits the growth of DU−145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 |
| 7337- | Gra, | Synergistic interactions among flavonoids and acetogenins in Graviola (Annona muricata) leaves confer protection against prostate cancer |
| - | in-vitro, | Pca, | NA |
| 7370- | HibSad, | Hibiscus sabdariffa leaf induces apoptosis of human prostate cancer cells in vitro and in vivo |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 7354- | HibSad, | Hibiscus sabdariffa Leaf Extract Inhibits Human Prostate Cancer Cell Invasion via Down-Regulation of Akt/NF-kB/MMP-9 Pathway |
| - | vitro+vivo, | Pca, | LNCaP |
| - | Trial, | Pca, | NA | - | Trial, | BC, | NA |
| 7741- | isoFl, | Lyco, | SIL, | Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement |
| - | Trial, | Pca, | NA |
| 7740- | isoFl, | Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial |
| - | Trial, | Pca, | NA |
| 7738- | isoFl, | Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced pro-inflammatory cytokines and immune suppressive cells |
| - | Trial, | Pca, | NA |
| 7987- | itraC, | Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer |
| - | Trial, | Pca, | NA |
| 8013- | itraC, | High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer |
| - | Case Report, | Pca, | NA |
| 8148- | lamb, | Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells |
| - | in-vitro, | Pca, | LNCaP |
| 7742- | Lyco, | isoFl, | Lycopene and soy isoflavones in the treatment of prostate cancer |
| - | Trial, | Pca, | NA |
| 7390- | MF, | A 60-Hz sinusoidal magnetic field induces apoptosis of prostate cancer cells through reactive oxygen species |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 3078- | RES, | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
| - | Review, | Pca, | NA |
| - | in-vitro, | Pca, | NA |
| 2406- | SFN, | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach |
| - | Review, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:1114 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid